|
[Related PubMed/MEDLINE] Total Number of Papers: 276
|
|
|
[Display Entries]
|
>> all entries
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2023 |
Incidence of and Risk Factors for Neonatal Hypothyroidism among Women with Graves' Disease Treated with Antithyroid Drugs until Delivery. |
ATD, GD, MMI, PTU |
2 |
2022 |
2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease. |
APAC, ATD, CBZ, GD, GO, MMI, PTU, RAI, TSH |
3 |
2022 |
Applicability of polygenic risk scores in endometriosis clinical presentation. |
PRS |
4 |
2022 |
Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. |
ATD, GD |
5 |
2022 |
Asymmetrical Graves' disease in children: potential usefulness of potassium iodide monotherapy. |
GD, TSH |
6 |
2022 |
Changes in Glucose Intolerance after Treatment with Antithyroid Drugs in Patients with Graves' Disease Using Continuous Glucose Monitoring: A Pilot Study. |
1,5-AG, CGM, CV, GD, MAGE, SD |
7 |
2022 |
Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism. |
GD, ROC, TSH, TSI |
8 |
2022 |
Different Characteristics of Orbital Soft Tissue Expansion in Graves Orbitopathy: Extraocular Muscle Expansion is Correlated to Disease Activity While Fat Tissue Volume With Duration. |
BV, BV, FV, GO, MV |
9 |
2022 |
How to manage Graves' disease in women of childbearing potential. |
ATDs, GD, RAI |
10 |
2022 |
Hyperthyroidism Presenting with Coronary Vasospasm. |
--- |
11 |
2022 |
Mathematical Modeling of Free Thyroxine Concentrations During Methimazole Treatment for Graves' Disease: Development and Validation of a Computer-Aided Thyroid Treatment Method. |
CATT, DigiThy, GD, MMI, TSH |
12 |
2022 |
MiR-29a-3p negatively regulates circulating Tfh memory cells in patients with Graves' disease by targeting ICOS. |
GD, ICOS, miRNAs, PBMCs |
13 |
2022 |
Novel Insight into Non-Genetic Risk Factors of Graves' Orbitopathy. |
GD, GO, TgAb |
14 |
2022 |
The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial. |
CIMT, FT4, ICAM-1, PTU, PWV, TSH, VCAM-1 |
15 |
2022 |
The prevalence and significance of nonuniform thyroid radio-isotope uptake in patients with Graves' disease. |
ATD, GD |
16 |
2022 |
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy. |
CAS, GO, RTX |
17 |
2022 |
TSH receptor antibodies (TRAb) - A potential new biomarker for endometriosis. |
FSH, FSHR, hCG, LH, LHR, TSH |
18 |
2021 |
Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre. |
AIATEs, GD, RRMS |
19 |
2021 |
Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report. |
MMI |
20 |
2021 |
Evaluation of the application of TSH receptor stimulating autoantibodies and the optimization of detection strategy in Graves' disease. |
AUC, TSI |
21 |
2021 |
Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). |
ATD, GD, ICPIs |
22 |
2021 |
Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. |
CAS, GO, RTX, SMD |
23 |
2021 |
Investigation of TSH receptor blocking antibodies in childhood-onset atrophic autoimmune thyroiditis. |
AAT, TSBAb |
24 |
2021 |
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. |
COVID-19, SARS-CoV-2, TgAb, TPOAb |
25 |
2021 |
Predicting the Course of Graves' Orbitopathy Using Serially Measured TSH-Receptor Autoantibodies by Automated Binding Immunoassays and the Functional Bioassay. |
GO, ROC |
26 |
2021 |
Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies. |
ATD, GD, GO |
27 |
2021 |
Rapid Differential Diagnosis of Thyrotoxicosis Using T3/T4 Ratio, FT3/FT4 Ratio and Color Doppler of Thyroid Gland. |
DT, GD |
28 |
2021 |
Role of the mononuclear cell infiltrate in Graves' orbitopathy (GO): results of a large cohort study. |
CAS, GO |
29 |
2021 |
Serum thyroglobulin is associated with orbitopathy in Graves' disease. |
GD, GO, TPOAb, TgAb |
30 |
2021 |
Targeted Temperature Management for In-hospital Cardiac Arrest Caused by Thyroid Storm: A Case Report. |
IHCA, ROSC, SCA, TSH, TTM, VF, VT |
31 |
2021 |
The Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Disease. |
--- |
32 |
2021 |
Third generation radioimmunoassay (RIA) for TSH receptor autoantibodies (TRAb) - one step less, similar results? |
AUC, GD, GDt, HD, HS, NAITD, RIA |
33 |
2021 |
Thyrotropin receptor antibody immunoassays may not be reliable in confirming diagnosis of Painless Thyroiditis. |
GD, PT, TCTU |
34 |
2021 |
[Graves' Disease]. |
AIT, GD, ICI |
35 |
2020 |
Auto regulatory capacity of the thyroid gland after numerous iodinated contrast media investigations. |
FT4, IC, TPOAb, TSH |
36 |
2020 |
fT3:fT4 ratio in Graves' disease - correlation with TRAb level, goiter size and age of onset. |
GD |
37 |
2020 |
Long-term outcomes of graves disease in children treated with anti-thyroid drugs. |
ATD, GD |
38 |
2020 |
Pitfalls in the assessment of gestational transient thyrotoxicosis. |
GD, GTT, hCG, TSH |
39 |
2020 |
The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism. |
GD |
40 |
2020 |
Use of Adjunctive Therapy to Achieve Preoperative Euthyroidism in Graves' Disease: A Case Report. |
FT4, TSH |
41 |
2019 |
A case of Graves' disease developing with exacerbation of sarcoidosis. |
--- |
42 |
2019 |
A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody. |
AUC, ELISAs, GD, HT, mAb, ROC, TSHR |
43 |
2019 |
Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications. |
DM, GD, GO |
44 |
2019 |
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy. |
ATD, CI, GD, HR, TgAb, TPOAb |
45 |
2019 |
Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. |
ICPIs, irAEs |
46 |
2019 |
Graves' hyperthyroidism in pregnancy. |
ATD, MMZ, PTU |
47 |
2019 |
High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease. |
GD, RAI, TSH |
48 |
2019 |
Hyperthyroidism and hypopituitarism: two incompatible diagnoses? |
--- |
49 |
2019 |
Liver enzyme profile and progression in association with thyroid autoimmunity in Graves' disease. |
ALP, AST, GD, GGT |
50 |
2019 |
Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. |
ATD, GH |
51 |
2019 |
Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy. |
cAMP, CAS, GO, TSAb |
52 |
2019 |
The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease. |
anti-Tg, anti-TPO, GD |
53 |
2019 |
Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients. |
--- |
54 |
2019 |
[Update Graves' disease 2019]. |
AIT, GD, PTU |
55 |
2018 |
Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. |
ATDs, GD, MS, RAI, TD |
56 |
2018 |
Characteristics of endometriosis: A case-cohort study showing elevated IgG titers against the TSH receptor (TRAb) and mental comorbidity. |
CI, OR, TPO, VAS-IBS |
57 |
2018 |
Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test. |
GD |
58 |
2018 |
False-positive TSH receptor antibody-a pitfall of third-generation TSH receptor antibody measurements in neonates. |
GD |
59 |
2018 |
Fetal hyperthyroidism associated with maternal thyroid autoantibodies: A case report. |
TSH |
60 |
2018 |
General hyperpigmentation induced by Grave's disease: A case report. |
ACTH, TSH |
61 |
2018 |
Graves' disease in clinical perspective. |
GD |
62 |
2018 |
Hypothyroidism conversion to hyperthyroidism: it's never too late. |
TPO |
63 |
2018 |
Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series. |
MS, TED |
64 |
2018 |
Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility. |
MTC, Tg, TgAb, TPOAb, TSH |
65 |
2018 |
Management of fetal goiters: 6-year retrospective observational study in three prenatal diagnosis and treatment centers of the Pays De Loire Perinatal Network. |
FBS |
66 |
2018 |
Morphea and antithyroid antibodies. |
TgAb, TSH |
67 |
2018 |
The Relation Between Epicardial Fat Tissue Thickness and TSH Receptor Antibody in Hyperthyroidism. |
EFT |
68 |
2018 |
Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases. |
GCs, TAO |
69 |
2018 |
Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves' disease. |
TSAb |
70 |
2018 |
TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy. |
BMD, GO |
71 |
2018 |
Utility of systematic TSHR gene testing in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy. |
TSHR |
72 |
2017 |
A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. |
RAI |
73 |
2017 |
Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy. |
GD, GO, IgG, IgG4 |
74 |
2017 |
Measuring TSH receptor antibody to influence treatment choices in Graves' disease. |
ATD, GD, GO, RAI |
75 |
2016 |
Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations. |
COX-2, GD, GO, PPARgamma |
76 |
2016 |
Changes in bone mineral density and trabecular bone score in Graves' disease patients after anti-thyroid therapy. |
BMD, IQR, TBS, TSH |
77 |
2016 |
Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves' Disease: A Prospective Pilot Study. |
MMI, TSH |
78 |
2016 |
GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE. |
ATD, GD, TSH |
79 |
2016 |
Graves Disease Induced by Radioiodine Therapy for Toxic Nodular Goiter: A Case Report. |
GD, MNG, RAIT, TA |
80 |
2016 |
High levels of DNA polymerase beta mRNA corresponding with the high activity in Graves' thyroid tissue. |
DNA poly beta, TSH |
81 |
2016 |
High prevalence of anti-TSH receptor antibody in fibromyalgia syndrome. |
AITD, FMS, TgAb, TPOAb, TSH |
82 |
2016 |
Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy. |
TPOAb, TSAb |
83 |
2016 |
Prevalence of Thyroid Nodules and Its Relationship with Iodine Status in Shanghai: a Population-based Study. |
TgAb, TNs, TPOAb, TSH, UICs |
84 |
2016 |
The Effect of Early Thyroidectomy on the Course of Active Graves' Orbitopathy (GO): A Retrospective Case Study. |
ATD, GO |
85 |
2016 |
The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds. |
CI, GD, SH |
86 |
2015 |
A 2013 European survey of clinical practice patterns in the management of Graves' disease. |
ATD, ETA, GD, RAI |
87 |
2015 |
Moyamoya disease concurrent with Graves' disease treated by direct bypass: clinical features and treatment strategies. |
GD, MMD, mRS, STA-MCA, TSH |
88 |
2015 |
Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy. |
AITD, CyA |
89 |
2015 |
Organ specificity in autoimmune diseases: thyroid and islet autoimmunity in alopecia areata. |
AA, Pc |
90 |
2015 |
Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs. |
ATDs |
91 |
2015 |
Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications. |
ATD, FT3 |
92 |
2015 |
TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients. |
CAS, GO, MRI, SEOMA, STIR |
93 |
2014 |
A Case of Marine-Lenhart Syndrome with a Negative TSH Receptor Antibody Titer Successfully Treated with a Fixed, Low Dose of I (131.). |
--- |
94 |
2014 |
Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset. |
GD, GO |
95 |
2014 |
Pregnancy after definitive treatment for Graves' disease--does treatment choice influence outcome? |
--- |
96 |
2014 |
Preoperative subclinical hyperthyroidism in patients with papillary thyroid carcinoma. |
ETE, PTC, TSH |
97 |
2014 |
Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study. |
CAS, GO, RTX |
98 |
2014 |
Risk factors for neonatal thyroid dysfunction in pregnancies complicated by Graves' disease. |
TSH |
99 |
2014 |
Severe fetal and neonatal hyperthyroidism years after surgical treatment of maternal Graves' disease. |
ATD, GA |
100 |
2014 |
Thymic hyperplasia in patients with Graves' disease. |
GD, TH |
|